IV Immunoglobulin Use Up in Interstitial Lung Disease

Share this content:
IV Immunoglobulin Use Up in Interstitial Lung Disease
IV Immunoglobulin Use Up in Interstitial Lung Disease

WEDNESDAY, Aug. 10, 2016 (HealthDay News) -- Intravenous immunoglobulin (IVIg) is increasingly being used for interstitial lung disease (ILD), despite a lack of evidence for its use, according to research published online Aug. 2 in the Annals of the American Thoracic Society.

Robert W. Hallowell, M.D., from Harvard Medical School in Boston, and colleagues explored use of IVIg and examined its role as potential adjunct therapy for ILD.

The researchers note that IVIg use has expanded in recent decades to include treatment of autoimmune and inflammatory disorders. IVIg has an immunomodulatory effect, acting via neutralization of pathogenic autoantibodies, alteration of immune cell effector function, suppression of cytokine and chemokine activity, and interference with activation of complement. IVIg is increasingly being used for treatment of ILD, which is a frequent complication of autoimmune disorders and connective tissue disease. No large studies are currently available to support the use of IVIg in ILD, but it is being used off-label for refractory cases that have failed to respond to standard immunosuppression. IVIg is more costly than traditional agents but is associated with less systemic toxicity and global immunosuppression.

"While IVIg is relatively well tolerated, it is much more expensive than traditional therapies, and there is currently not adequate data to support its routine use in this context," the authors write. "As such, clinical trials are necessary to determine if IVIg has a role in the treatment of ILD."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Post-C-Section Cephalexin, Metronidazole Cuts SSI Rate

Post-C-Section Cephalexin, Metronidazole Cuts SSI Rate

Post-op course reduces rate of surgical site infection within 30 days of C-section among obese women

Multicomponent Intervention Linked to Greater Drop in BP

Multicomponent Intervention Linked to Greater Drop in BP

Intervention beneficial over 18 months for low-income adults in Argentina with uncontrolled HTN

Total of 0.21 Years Lost Due to Opioid-Related Poisoning Deaths

Total of 0.21 Years Lost Due to Opioid-Related ...

Drug-related poisoning deaths up from 2000 to 2015, with most of the increase due to opioid deaths

is free, fast, and customized just for you!

Already a member?

Sign In Now »